Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET
نویسندگان
چکیده
In this Part II review, as a complement to the Part I published in this supplement, the authors cover the imaging techniques that evaluates the Alzheimer's disease according to the different metabolic and molecular profiles. In this section MR spectroscopy, FDG-PET and amyloid PET are deeply discussed.
منابع مشابه
The diagnostic difference between 18F- FDG PET and 99mTc-HMPAO SPECT perfusion imaging in assessment of Alzheimer's disease
Introduction:Brain imaging with F-18 fluorodeoxyglucose (18F-FDG) positron emission tomography or Tc-99m hexamethylpropyleneamine oxime (99mTc-HMPAO) SPECT is widely used for the evaluation of Alzheimer's dementia (AD); we aim to assess superiority of one method over the other. Methods: Twenty four patients with clinical diagnosi...
متن کاملMultimodality imaging of Alzheimer disease and other neurodegenerative dementias.
Neurodegenerative diseases, such as Alzheimer disease, result in cognitive decline and dementia and are a leading cause of mortality in the growing elderly population. These progressive diseases typically have an insidious onset, with overlapping clinical features early in the disease course that make diagnosis challenging. The neurodegenerative diseases are associated with characteristic, alth...
متن کاملDetection of Alzheimer\\\\\\\'s Disease using Multitracer Positron Emission Tomography Imaging
Alzheimer's disease is characterized by impaired glucose metabolism and demonstration of amyloid plaques. Individual positron emission tomography tracers may reveal specific signs of pathology that is not readily apparent on inspection of another one. Combination of multitracer positron emission tomography imaging yields promising results. In this paper, 57 Alzheimer's disease neuroimaging ini...
متن کاملImaging Brain Metabolism and Pathology in Alzheimer’s Disease with Positron Emission Tomography
Current Positron Emission Tomography (PET) biomarkers for Alzheimer's disease (AD) assess either neuronal function, or associated pathological features of this common neurodegenerative disease. The most widely accepted clinical PET tool for AD is 18-fluorodeoxyglucose PET (FDG-PET), which measures cerebral metabolic glucose utilization rate (CMRglc). FDG-PET is a marker of synaptic activity, ne...
متن کامل18F-FDG PET/CT findings in a possible MELAS syndrome: A case study
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a rare congenital disorder of mitochondrial DNA, presenting a wide range of clinical symptoms comprising headaches, seizures, aphasia, hearing loss, visual defects, and hemiparesis. Herein we report a case of a previously asymptomatic 40-year-old male who presented with recurrent headache, seiz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 9 شماره
صفحات -
تاریخ انتشار 2015